Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

被引：539

作者：

Mega, Jessica L. ^{[1
,2
]}

Close, Sandra L. ^{[3
]}

Wiviott, Stephen D. ^{[1
,2
]}

Shen, Lei ^{[3
]}

Hockett, Richard D. ^{[4
]}

Brandt, John T. ^{[3
]}

Walker, Joseph R. ^{[5
]}

Antman, Elliott M. ^{[1
,2
]}

Macias, William L. ^{[3
]}

Braunwald, Eugene ^{[1
,2
]}

Sabatine, Marc S. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, TIMI Study Grp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Affymetrix, Santa Clara, CA USA

[5] Daiichi Sankyo Inc, Parsippany, NJ USA

来源：

CIRCULATION | 2009年 / 119卷 / 19期

关键词：

cardiovascular diseases; drugs; genetics; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; THIENOPYRIDINE ANTIPLATELET AGENT; ELEVATION MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; 2007 FOCUSED UPDATE; STENT THROMBOSIS; CLOPIDOGREL RESPONSIVENESS; PLATELET INHIBITION; ACTIVE METABOLITE;

D O I：

10.1161/CIRCULATIONAHA.109.851949

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background-Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of reduced-function CYP2C19 alleles have significantly lower levels of active metabolite, diminished platelet inhibition, and higher rates of adverse cardiovascular events. The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown. Methods and Results-The associations between functional variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to prasugrel were tested in 238 healthy subjects. We then examined the association of these genetic variants with cardiovascular outcomes in a cohort of 1466 patients with acute coronary syndromes allocated to treatment with prasugrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 trial. Among the healthy subjects, no significant attenuation of the pharmacokinetic or the pharmacodynamic response to prasugrel was observed in carriers versus noncarriers of at least 1 reduced-function allele for any of the CYP genes tested (CYP2C19, CYP2C9, CYP2B6, CYP3A5, and CYP1A2). Consistent with these findings, in subjects with acute coronary syndromes treated with prasugrel, no significant associations were found between any of the tested CYP genotypes and risk of cardiovascular death, myocardial infarction, or stroke. Conclusions-Common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel. These pharmacogenetic findings are in contrast to observations with clopidogrel, which may explain, in part, the different pharmacological and clinical responses to the 2 medications. (Circulation. 2009; 119: 2553-2560.)

引用

页码：2553 / U44

页数：14

共 42 条

[21]

Karolinska Institutet, HUM CYT P450 CYP ALL

[22] The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance [J].

Kim, K. A. ;

Park, P. W. ;

Hong, S. J. ;

Park, J-Y .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) :236-242

[23] 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention [J].

King, Spencer B., III ;

Smith, Sidney C., Jr. ;

Hirshfeld, John W., Jr. ;

Jacobs, Alice K. ;

Morrison, Douglass A. ;

Williams, David O. ;

Feldman, Ted E. ;

Kern, Morton J. ;

O'Neill, William W. ;

Schaff, Hartzell V. ;

Whitlow, Patrick L. ;

Adams, Cynthia D. ;

Anderson, Jeffrey L. ;

Buller, Christopher E. ;

Creager, Mark A. ;

Ettinger, Steven M. ;

Halperin, Jonathan L. ;

Hunt, Sharon A. ;

Krumholz, Harlan M. ;

Kushner, Frederick G. ;

Lytle, Bruce W. ;

Nishimura, Rick ;

Page, Richard L. ;

Riegel, Barbara ;

Tarkington, Lynn G. ;

Yancy, Clyde W. .

CIRCULATION, 2008, 117 (02) :261-295

[24]

Kurihara A., 2005, DRUG METAB REV S2, V37, P99

[25] Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction [J].

Matetzky, S ;

Shenkman, B ;

Guetta, V ;

Schechter, M ;

Bienart, R ;

Goldenberg, I ;

Novikov, I ;

Pres, H ;

Savion, N ;

Varon, D ;

Hod, H .

CIRCULATION, 2004, 109 (25) :3171-3175

[26] Cytochrome P-450 Polymorphisms and Response to Clopidogrel. [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William ;

Braunwald, Eugene ;

Sabatine, Marc S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (04) :354-362

[27] Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations [J].

Myrand, S. P. ;

Sekiguchi, K. ;

Man, M. Z. ;

Lin, X. ;

Tzeng, R-Y ;

Teng, C-H ;

Hee, B. ;

Garrett, M. ;

Kikkawa, H. ;

Lin, C-Y ;

Eddy, S. M. ;

Dostalik, J. ;

Mount, J. ;

Azuma, J. ;

Fujio, Y. ;

Jang, I-J ;

Shin, S-G ;

Bleavins, M. R. ;

Williams, J. A. ;

Paulauskis, J. D. ;

Wilner, K. D. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :347-361

[28] Clopidogrel response variability and future therapies - Clopidogrel: Does one size fit all? [J].

O'Donoghue, Michelle ;

Wiviott, Stephen D. .

CIRCULATION, 2006, 114 (22) :E600-E606

[29] Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel [J].

Payne, Christopher D. ;

Li, Ying Grace ;

Small, David S. ;

Ernest, C. Steven, II ;

Farid, Nagy A. ;

Jakubowski, Joseph A. ;

Brandt, John T. ;

Salazar, Daniel E. ;

Winters, Kenneth J. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) :555-562

[30] Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 [J].

Rehmel, JLF ;

Eckstein, JA ;

Farid, NA ;

Heim, JB ;

Kasper, SC ;

Kurihara, A ;

Wrighton, SA ;

Ring, BJ .

DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) :600-607

← 1 2 3 4 5 →